Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul 4;49(4):833-835.
doi: 10.1093/schbul/sbad037.

Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis

Sri Mahavir Agarwal  1   2   3   4 , Nicolette Stogios  1   2 , Guy E J Faulkner  5 , Margaret Hahn  1   2   3   4
Affiliations
Meta-Analysis

Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis

Sri Mahavir Agarwal et al. Schizophr Bull. .

Abstract

Patients with schizophrenia are burdened by higher rates of obesity, cardiovascular disease and reduced life expectancy than the general population. In addition to illness, genetic and lifestyle factors, the associated weight gain and metabolic adverse effects of antipsychotic (AP) medications are known to exacerbate and accelerate these cardiometabolic problems significantly. Given the detrimental consequences of weight gain and other metabolic disturbances, there is an urgent need for safe and effective strategies to manage these issues as early on as possible. This review summarizes the literature of adjunctive pharmacological interventions aimed at preventing AP-induced weight gain.

Keywords: adjunctive medications; antipsychotic-induced weight gain; cochrane; meta-analysis; prevention; systematic review.

PubMed Disclaimer

Conflict of interest statement

MH has consultant fees from Alkermes, Inc. However, she declares that she did not receive any direct payment for completion of this review. All other funding details and conflicts of interest can be found in the main Cochrane report.

Figures

Fig. 1.
Fig. 1.
Average endpoint/change in weight outcomes with (A) Metformin, (B) H2 Antagonists, (C) Monoamine Modulators, and (D) Topiramate.
See this image and copyright information in PMC

References

    1. Agarwal SM, Stogios N, Ahsan ZA, et al. . Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database Syst Rev. 2022;10(10):1–139. doi:10.1002/14651858.CD013337.pub2. - DOI - PMC - PubMed

MeSH terms

Substances